Skip to main content
Fig. 1 | BMC Musculoskeletal Disorders

Fig. 1

From: Changes in clinical symptoms and functional disability in patients with coexisting patellofemoral and tibiofemoral osteoarthritis: a 1-year prospective cohort study

Fig. 1

Changes in VAS in the subpopulation of patients with coexisting PFOA at 1 year follow-up. a, Trajectories of VAS scores. Categorized pain scale grades are also shown in the same panel (no, mild, moderate, and severe). The clinically important borderline between mild and moderate pain (VAS score = 30 mm) is displayed as a solid horizontal line. Other borderline values on the categorized pain scale are displayed as dotted horizontal lines. White squares connected with dotted lines represent the mean change in VAS score of each group. *Significantly different (P < 0.05) after adjusting for age, sex, and body mass index in a post-hoc analysis of two-way repeated analysis of covariance (time effect: adjusted P-value = 0.385, group effect: adjusted P-value = 0.033, time-group interaction: adjusted P-value = 0.167, as shown in Table 4). b, Numbers and percentages of patients with moderate or more severe pain (i.e., moderate [30 mm < VAS ≤ 60 mm] and severe [VAS > 60 mm]) corresponding to a state with unacceptable symptoms and considered a clinically relevant treatment target [31, 34, 35]. Unadjusted P-values were calculated using the chi-square test. † P-values corresponding to significant differences are displayed in bold

Back to article page